OTC Pink Basic Disclosure Guidelines

1) Name of the Issuer and its predecessors (if any)

CTT Pharmaceutical Holdings, Inc. is a Nevada Corporation, incorporated on November 6, 1996 under the name Winchester Mining Corp. The name of the Company was changed to PNW Capital, Inc. on May 16, 2000. In 2002, PNW Capital, Inc. acquired Industrial Minerals Incorporated and changed its name to Industrial Minerals, Inc. Effective July 26, 2011, the Company changed its name to Mindesta Inc.

In conjunction with the acquisition of CTT Pharmaceuticals Inc., effective July 20, 2015 we changed our name to CTT Pharmaceutical Holdings, Inc. ("CTT Pharmaceuticals").

2) Address of the Issuer's principal executive offices

Company Headquarters

429 Kent Street unit 112
Ottawa, Ontario, Canada K2P 2B4
Phone:(289)348-1374
Email: pankaj03@msn.com
www.cttpharmaceuticals.com

IR Contact

Not applicable.

3) Security Information

Item 3: Security Information

The Company is authorized to issue 300,000,000 shares of common stock and 10,000,000 preferred shares.

Common Stock:

The par value of the Company's common stock is $0.0001 per share

The Company's CUSIP Number is: 12651E106.

The Company's Trading Symbol is: CTTH

At March 31, 2016 and December 31, 2015 there were 21,319,302 shares of common stock issued and outstanding.

Preferred Shares:

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value.
There are no Preferred Shares issues or outstanding.

Transfer Agent

Heritage Transfer Agency Inc
4 King Street W. Suite 1320
Toronto, Ontario M5H 1B6 Canada
Telephone Number: (416)364-9509
Registered Under the Exchange Act: Yes

List any restrictions on the transfer of security: None except as provided by Rule 144.

Describe any trading suspension orders issued by the SEC in the past 12 months.

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On July 20, 2015 the Company reverse split its issued and outstanding shares of common stock on a 1:10 basis

4) Issuance History

During the past two years the following securities were issued:

On September 9, 2014 the Company. entered into a Share Exchange Agreement (the " Exchange Agreement") with CTT Pharmaceuticals, Inc., and the shareholders of CTT Pharma whereby the Company acquired all of the issued and outstanding shares of common stock of CTT Pharma in consideration for the issuance of 149,183,285 shares of our common stock.

The shares of common stock were not registered in any jurisdiction.

All of the shares issued contained a restrictive legend.

With respect to the sale of the securities identified above, we relied on the exemption provisions of Section 4(2), of the Securities Act, as amended.

The shares of common stock were not registered in any jurisdiction.

During the year ended 2015, the Company issued a total of 1,812,500 (post split) shares of common stock for services rendered including financial reporting, brand management, social media, marketing and videography.

5) Financial Statements

We are providing with the supplemental information the following financial statements:

- Consolidated Balance Sheets at March 31, 2016 and December 31, 2015 (unaudited)
- Consolidated Statement of Operations for the three months ended March 31, 2016 and 2015 (unaudited)
- Consolidated Statement of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)
- Statement of Stockholders' Equity for the period ended March 31, 2016.
- Notes to Unaudited Financial Statements

The financial statements requested pursuant to this item were prepared in accordance with US GAAP by persons with sufficient financial skills.

6) Describe the Issuer's Business, Products and Services

A. Description of the issuer's business operations;

The Company's wholly owned subsidiary, CTT Pharmaceutical Holdings, Inc. ("CTT Pharma") specializes in drug delivery systems technology within the pharmaceutical industry. CTT Pharma's focus is fast dissolving drug delivery systems. The Company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts (THC, annabinoids, Terpenes) to deliver treatment as an alternate to smoking and ingestion.

CTT Pharma is a developmental stage company which has had limited operations to date. Its principal asset is a patented orally administered wafer (the "Wafer").

The Wafer is an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The wafer is

formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer formulation relates to a rapidly dissolving formulation suitable for oral administration.

The wafer is treated with a pharmaceutical agent designed to reduce or treat a medical condition.

It is anticipated that CTT Pharma will develop a cannabis based wafer formulated for pain relief and the side effects of cancer treatment.

The wafer is an orally administrable paper-thin polymer films used as carriers for pharmaceutical agents. The Wafer rapidly dissolves to release the pharmaceutical agent as soon as it comes in contact with saliva, thus obviating the need for water during administration. This attribute makes the wafer highly attractive for pediatric and geriatric patients due to the difficulty in swallowing conventional tablets and capsules.

Delivery of a pharmaceutical agent via an orally administrable wafer provides a mechanism for rapid access to the activity of the pharmaceutical agent in comparison with currently available orally administrable formulations. The wafer exhibits a very rapid rate of dissolution in an aqueous environment and, thus, provides expedited delivery of a pharmaceutical agent which translates into accelerated access to the activity of the pharmaceutical agent.

B. Date and State (or Jurisdiction) of Incorporation:

The Issuer is a Nevada corporation, incorporated on November 6, 1996

C. the issuer's primary and secondary SIC Codes;

The Company's primary SIC code is: 2834
The Company's secondary SIC code is: 2836

D. the issuer's fiscal year end date: December 31

E. principal products or services, and their markets;

Included as part of the Issuer's disclosure under business operations.

7) Describe the Issuer's Facilities

The Company's principal place of business is located at 429 Kent Street unit 112, Ottawa, Ontario, Canada K2P 2B4. The Company leases this space at no cost to the Company from a corporate officer. Until such time as the Company becomes operational, management believes that this space is sufficient.

8) Officers, Directors, and Control Persons

Our executive officers and directors at March 31, 2016 were:

Name	Position(s) and Office(s)
Dr. Pankaj Modi	CEO/CFO/PRESIDENT/ DIRECTOR
Dr. Allen Greenspoon	DIRECTOR
Dean Hanisch	SECRETARY/ DIRECTOR

Pankaj Modi: Since September 9, 2014 Dr. Modi has served as our Chief Executive Officer and Director**.** In 2007 Dr. Modi founded CTT Pharma. He was the original patent owner of our wafer and has been instrumental in formulating various uses for the wafer. In 2006 he founded Transdermal Tech. Dr. Pankaj Modi, MD, PhD is a clinician and research scientist with experience in numerous medical areas. He is founder and president of NeoMed Chemotherapeutics Corp, which is developing a cancer treatment option, founder and president of Transdermal Corp, a dermatological specialty products company, co-founder and president of SoftTouch Corp, which developed a minimally invasive micro-needle device for injectable drugs, and founder and president of Photodyne Therapeutics Corp, which developed a novel dermatological therapy.

Dr. Allen Greenspoon, MD. Since September 9, 2014, Dr. Greenspoon has served as a corporate director.Dr. Greenspoon has been
a practicing physician specializing in obstetrics and occupational health for over 25 years working in Hamilton, Ontario. He has been conducted multiple clinical research studies related diabetes, lipids (cholesterol) management, dermatology, obesity, oncology related research and cardiovascular diseases. He is the founder of Wellington@Work and the owner of Wellington Medical Centre. He also serves as a director of several privately held biotech companies.

Dean Hanisch: Since September 9, 2014 has held various positions with the Company. Mr. Hanisch has served as our president, secretary and as a director. Mr. Hanisch has over 15 years experience in business and finance. Since October 2012 he has Worked for Steenberg Financial as a consultant for the Company's North American brokerage services. From 2012 to 2013 he served as the Interim chief executive officer for Mazorro Resources, an exploration stage mining company. From 2006 through 2011 he served as the Director of Business Development and Strategy for Paramount Gold and Silver Corp,. an exploratory stage mining company trading on the NYSE (PZG), TSX (PZG) and Deutsche Borse (P6G).

B. **Legal/Disciplinary History**

During the past five years, no director, nominee for director or any executive officer of Union Dental Holdings:

1. Filed a petition under the Federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

2. Been convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

3. Was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

   i. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

   ii. Engaging in any type of business practice; or

   iii. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

4. Was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity; or

5. Was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated.

6. Was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated.

C. The table below sets forth the number and percentage of shares of our equity securities owned as March 31, 2016, by the following persons: (i) stockholders known to us who own 5% or more of our outstanding shares and; each of our executive officers and directors, and (iii) our executive officers and directors as a group.

As of March 31, 2016 there were 21,319,302 shares of common stock issued and outstanding.

Name and Address	No of Shares of Common Stock	Percent of Class
Pankaj Modi 519 Golf Links Road Ancaster, Ontario L9G 4X9	7,036,947	33.0%
Dean Hanisch 326 River Road Ottawa, Ontario KIV 1H2	1,407,889	6.6%
Allen Greenspoon M1-414 Victoria Ave. N. Hamilton, ON L8L 5G8	333,333	1.5%
Lucie Letellier 88 Ramsay Road Chelseam Quebec, J9B 2J1	500,000	2.3%-
Heshan Osman 716 Vermillion Drive Gloucester, Ontario K1B 1V9	2,097,010	9.8%
Capital Financial Camay Rabay, principal; SGBL Bank street, Beyrouth, Lebanon	2,847,489	13.3%

9) Third Party Providers

Legal Counsel

Name: Jeffrey G. Klein. Esq.
Firm: Jeffrey G. Klein, PA
301 Yamato Road
Suite 1240
Boca Raton, FL 33431
Office: (561)953-1126
Fax: (561)994-6693
Cell: (561)414-1640
jklein@jkleinlegal.com

Accountant or Auditor

The Company's financial statements are prepared by:

Tracy Albert, CPA
1892 Rocklane Dr
Kanata, ON
Canada K2W 1B5
613-470-5647
E-mail: tracyalbert@rogers.com

Investor Relations

Not applicable

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

N/A

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

1. I have reviewed this disclosure statement of CTT Pharmaceuticals, Inc. ;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

/s/Dr. Pankaj Modi Dated: May 16, 2016

Dr. Pankaj Modi, CEO and Director